Prescribing information



Dr Paul Nathan presents the data on the use of Tafinlar (dabrafenib) + Mekinist (trametinib) in the adjuvant setting for management of adult patients with BRAF V600 stage III melanoma, following complete resection. Filmed August 2018.

Rate this content: 
No votes yet
TMC20-C016 March 2020

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]